| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Butyrophilin subfamily 2 member A1, BTN2A1, BT21, BTF1 |
| Entrez GeneID | 11120 |
| WB Predicted band size | 59.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This BTN2A1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 344-373 amino acids from the C-terminal region of human BTN2A1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于BTN2A1抗体的3篇示例文献(注：部分内容为简化示例，实际文献需通过数据库检索确认)：
---
1. **文献名称**: *BTN2A1 regulates γδ T cell activation through antigen-presenting cell interactions*
**作者**: Smith A, et al. (2022)
**摘要**: 本研究利用抗BTN2A1单克隆抗体阻断实验，发现BTN2A1通过调控抗原呈递细胞与γδ T细胞的相互作用，影响T细胞活化和抗肿瘤免疫应答。抗体阻断显著抑制了炎症因子释放。
---
2. **文献名称**: *Development of a high-affinity anti-BTN2A1 antibody for cancer immunotherapy*
**作者**: Li X, et al. (2021)
**摘要**: 报道了一种新型人源化抗BTN2A1抗体的开发，该抗体通过结合BTN2A1胞外域抑制肿瘤细胞免疫逃逸。实验显示其可增强PD-1抑制剂在黑色素瘤模型中的疗效。
---
3. **文献名称**: *BTN2A1 as a biomarker in triple-negative breast cancer: immunohistochemical analysis*
**作者**: Gomez-Ruiz JA, et al. (2020)
**摘要**: 使用抗BTN2A1多克隆抗体对乳腺癌组织进行染色，发现BTN2A1高表达与患者生存率正相关，提示其可能作为三阴性乳腺癌的预后标志物。
---
**建议**：以上为示例，实际文献可通过PubMed或Google Scholar以关键词“BTN2A1 antibody”或“BTN2A1 immune function”检索，并筛选涉及抗体开发、功能研究或临床应用的论文。
BTN2A1 (Butyrophilin Subfamily 2 Member A1) is a transmembrane protein belonging to the B7-like family of immune regulators, which plays a role in modulating T-cell responses. Structurally, it contains immunoglobulin (Ig)-like domains and shares homology with other butyrophilin proteins involved in lipid antigen presentation and γδ T-cell activation. BTN2A1 is expressed in various tissues, including immune cells, epithelial cells, and certain cancers. Its function remains incompletely understood, but studies suggest it may interact with BTN3A1 to regulate γδ T-cell receptor activation, particularly in response to phosphoantigens produced during cellular stress or infection.
Antibodies targeting BTN2A1 are primarily used as research tools to investigate its biological roles, expression patterns, and therapeutic potential. They enable detection via techniques like flow cytometry, immunohistochemistry, and Western blotting. Recent research highlights BTN2A1's involvement in immune evasion mechanisms in tumors, where its expression correlates with altered T-cell activity. Additionally, BTN2A1 antibodies have been explored in preclinical studies to manipulate γδ T-cell-mediated anti-cancer responses, suggesting possible applications in immunotherapy. Commercial BTN2A1 antibodies are typically monoclonal or polyclonal, validated for specificity in human or murine models, though functional characterization remains an active area due to the protein’s complex interactions within the immune network. Further studies are needed to clarify its ligand-binding partners and downstream signaling pathways.
×
